Status:

COMPLETED

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Lead Sponsor:

PETHEMA Foundation

Conditions:

Acute Promyelocytic Leukemia

Eligibility:

All Genders

Up to 75 years

Phase:

PHASE4

Brief Summary

Primary objectives * To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL. * To evaluate the impact of mit...

Detailed Description

Treatment of induction with the simultaneous administration of ATRA (45 mg/m2 day until the RC) and idarubicine (12 mg/m2 days 2, 4, 6 and 8), 3 monthly cycles of consolidation with ATRA (45 mg/m2 day...

Eligibility Criteria

Inclusion

  • Age ≤ 75 years.
  • ECOG ≤ 3.
  • Morphologic Diagnosis of LPA (FAB M3 or variant M3). Those cases without typical morphology but with PML-RARα reordering also must be including.
  • Genetic Diagnosis: t (15; 17) demonstrated by cariotipo conventional, FISH, PML-RARα reordering detected by RT-PCR or a pattern microspeckled demonstrated with antibody anti-PML (positive PGM3). Obvious, it will be had the result of these tests once initiated the treatment on the basis of a suspicion diagnoses morphologic

Exclusion

  • Age \>75 years (the treatment with this protocol can be considered individually)
  • Absence of PML-Rare reordering.
  • To have received previously some type of treatment for LPA, including chemotherapy or retinoides. The previous treatment with corticoids, hidroxiurea or leucoaféresis is not reason for exclusion.
  • To have received chemotherapy or x-ray for the treatment of a disease vitiates previous.
  • Associate Neoplasia.
  • Serious psychiatric Disease.
  • Seropositividad for VIH.
  • Contraindication to receive intensive chemotherapy, specially antraciclinas.
  • Sérica Creatinina ≥ 2,5 mg/dL (≥ 250 μmol/l).
  • Bilirrubina, fosfatasa alkaline, or GOT \> 3 times the normal limit
  • Test of positive pregnancy.

Key Trial Info

Start Date :

July 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2013

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT00408278

Start Date

July 1 2005

End Date

December 1 2013

Last Update

October 28 2014

Active Locations (42)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (42 locations)

1

PALG

Lodz, Poland

2

Hospital Juan Canalejo

A Coruña, Spain

3

Hospital General

Albacete, Spain

4

Hospital general

Alicante, Spain

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | DecenTrialz